Vitrafy Life Sciences

Pioneering Technology, *Preserving Life.*

Building the foundational infrastructure for the global biologics economy.

Q1 FY2027 Quarterly Update

Important Notice and Disclaimer

This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (the Company). Statements in this presentation are made only as at the date of this presentation and the information in this presentation remains subject to change without notice. The information in this presentation is of a general nature and does not purport to be complete, is provided solely for information purposes of giving you summary information and background about the Company and its activities, current as at 28 October 2026 and should not be relied upon by the recipient.

This presentation is not, and does not constitute, or form any part of, an offer to sell or issue, or the solicitation, invitation or recommendation to purchase any securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. This presentation does not purport to summarise all information that a recipient should consider when making an investment decision, and should not form the basis of any decision by a recipient.

Recipients should carry out their own investigations and analysis of the Company and verify the accuracy, reliability and completeness of the information contained in this presentation or any other form of communication to which the recipient is permitted access in the course of evaluating an investment in the Company.

No liability
To the maximum extent permitted by law, the Company, or their respective affiliates or related bodies corporate or any of their respective officers, directors, employees, agents and advisers (Related Parties), nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning, the content of this presentation, the Company, or the Company's securities including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

Eligible recipients
This presentation is provided to you as an investor to whom an offer document is not required to be given, and no registration, lodgement or other formality is required, in connection with an offer of securities. In accepting this presentation you warrant that you are an investor within the scope of this paragraph and that you accept this presentation on the basis set out in this notice.

This presentation is not, and does not constitute, or form any part of, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. This presentation may not be distributed or released in the United States. Securities may not be offered or sold in the United States unless such securities are registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act) or in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities laws. Each institution or person that reviews this presentation will be deemed to represent that each such institution or person is not in the United States.

The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

Confidentiality
This presentation is confidential and not for further distribution. It is provided by the Company on the basis that, by accepting this presentation, persons to whom this presentation is given agree to keep the information confidential, not copy the presentation and not to disclose it, in whole or in part, to anyone within their organisation except on a need-to-know basis and subject to these restrictions, or to anyone outside their organisation.

Not financial product advice
Reliance should not be placed on the information or opinions contained in this presentation. This presentation is for informational purposes only and is not financial product or investment advice or a recommendation to acquire the Company's securities and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. You should make your own assessment of an investment in the Company and should not rely on this presentation. In all cases, you should conduct your own research of the Company and analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of the Company and its business, and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.

Past performance
Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as an indication of (and gives no guidance as to) future performance.

Future performance
This presentation contains certain forward-looking statements (including financial forecasts) with respect to the financial condition, operations and business of the Company and certain plans and objectives of the management of the Company. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms "believes", "estimates", "anticipates", "expects, "predicts", "intends", "plans", "goals", "targets", "aims", "outlook", "guidance", "forecasts", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts.

Such forward looking statements involve known and unknown risks, uncertainties and other factors which because of their nature may cause the actual results or performance of the Company to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which the Company will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts.

Forward-looking statements speak only as at the date of this presentation and to the full extent permitted by law, the Company and its respective affiliates and related bodies corporate and each of their respective Related Parties and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Financial data
All figures in the presentation are Australian dollars ($ or A$) unless stated otherwise. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.

Financial information
The pro forma financial information provided in this presentation is for illustrative purposes only and does not represent a forecast or expectation as to the Company's future financial condition and/or performance. This document has been prepared at a time where the review of financial information contained in this presentation has not been completed and accordingly, you should only rely on any expectation as to the Company's future financial condition and/or performance that is contained in a prospectus or other offering document which may be issued by the Company in connection with any offer of the Company's securities.

Acknowledgement
Persons who access, receive, review or attend this presentation are required to inform themselves of, and comply with, all of the above restrictions and prohibitions and none of the Company or the Related Parties accepts any liability to any person in relation thereto. This presentation is made to you on the basis that by attending, accessing or receiving or reviewing this presentation, you confirm that you understand and agree to the contents of this important notice and disclaimer and that you are a person to whom this presentation may lawfully be made in accordance with laws applicable to you, including those of the jurisdiction in which you are located.

Q1 FY27 HIGHLIGHTS

A Clear Step Up in U.S. Momentum

Blood partnerships executed, CGT entry secured, leading Scientific Advisory Board set-up and FDA listing on track.

3rd

Major U.S. civilian blood partner secured – Versiti

~17%

Exposure to U.S. civilian blood collection sites across partners up from zero at the start of the year

1st

U.S. cell & gene therapy agreement secured – Charter Medical

SAB

Established a Scientific Advisory Board comprising leading global human health experts

9

Guardion devices manufactured with Medical Device Listing on track for 1H FY2027

$38.3m

Cash and term deposits at 30 September 2026

vitrafy LIFE SCIENCES

BLOOD

U.S. Blood Network

Three civilian partnerships plus the U.S. Army, giving exposure to civilian and sovereign blood networks.



Blood Partners

vitalant Innovation Center

Partnership Focus: Red blood cells

versiti™

Partnership Focus: Platelets and Plasma

Hoxworth BLOOD CENTER
UNIVERSITY OF CINCINNATI

Partnership Focus: Red blood cells

UNITED STATES ARMY INSTITUTE OF SURGICAL RESEARCH

Partnership Focus: Platelets and Plasma

3	U.S. civilian blood partners + U.S. military	**~179**	fixed collection sites	**~2.4m**	units collected annually by Vitrafy partners	**~17%**	of U.S. blood collection sites across partners

Partner exposure based on ~2.4m of ~14.2m annual U.S. blood collections. Fixed sites exclude mobile collections. Industry logos are examples only and do not represent agreements.

vitrafy LIFE SCIENCES

MARKET DEVELOPMENT

Growing Recognition Across the Industry

AABB 2026 put Vitrafy in front of the blood and biotherapies industry leaders, with panel presentations and the introduction of our new Scientific Advisory Board.

Scientific Advisory Board

Launched at AABB 2026 to advise on scientific, regulatory and commercial development.

Transfusion medicine

Pampee Young

MD, PhD

American Red Cross

Cell therapy

Jose Cancelas

MD, PhD

Dana-Farber Cancer Institute

Cell & gene therapy

Folashade Otegbeye

MD, MPH

Fred Hutch Cancer Center

Trauma care

Don Jenkins

MD

UT Health San Antonio

Biostatistics

Richard Cook

PhD

University of Waterloo

MARKET DEVELOPMENT

Growing Recognition Across the Industry

2026 ATLANTA OCTOBER 17-19

Vitrafy also presented its cryopreservation ecosystem and the results of its cryopreserved platelets study were presented by Kristin Reddoch-Cardenas of USAISR.

EXPANDING APPLICATIONS

Cell & Gene Therapy and Animal Health

One cryopreservation platform, multiple markets.

Cell & Gene Therapy

Charter Medical

- Entry into the U.S. cell and gene therapy market
- Guardion + LifeChain at its North Carolina Innovation Hub
- Freeze-curve optimisation studies for its customers

Animal Health

IMV Technologies

- Testing and validation continued in Q1 FY2027
- Focus: proving commercial viability
- Program continues through Q2 FY27

300	CDMOs operating in the U.S.	**1,800**	CGT Manufacturers in North America	**2,200**	Animal collection sites

vitrafy LIFE SCIENCES

PRODUCT & OPERATIONS

Guardion Device Manufacturing

Device fleet scaling across research use, into Medical Device manufacturing Q3 FY2027 following FDA regulatory milestone

Guardion devices built per quarter



Guardion Manufacturing

- 9 Guardion devices were built during quarter for partner use and medical device testing
- Verification and validation work well progressed ahead of Medical Device listing in 1H FY2027
- First medical device fleet production commencing early 2H FY27
- U.S. manufacturing on stream in the second half of 2027

vitrafy LIFE SCIENCES

FINANCIAL POSITION

Strong Funding Position Supporting Scale Up

Spend shifting from product development to manufacturing, validation and market development.

$38.3m

Cash and term deposits at 30 September 2026

$4.9m

Net operating cash outflow in Q1 FY27

~$1.9m

Average monthly cash burn

~7.9

Quarters of funding available[1]



[1] Based on Q1 FY27 net operating cash outflow; refer Appendix 4C section 8.5. Q1 receipts: customers $0.1m, government grants $0.3m, interest $0.4m.

vitrafy LIFE SCIENCES

OUTLOOK

Building Towards FDA Listing

Device fleet scaling, regulatory milestone approaching and U.S. team strengthened.

H1 FY27

- Guardion U.S. FDA medical device listing
- U.S Headquarters secured with CEO relocation
- Converting pipeline opportunities across the U.S Blood and CGT network

H2 FY27

- First medical device fleet manufactured
- Aus based CFO start Feb 2027 – Jan Gielen

vitrafy LIFE SCIENCES